Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival

The Journal of Urology
Cheryl T LeeDavid P Wood

Abstract

Some groups hypothesize that a delay in cystectomy may result in higher pathological stage and possibly alter survival in patients with bladder cancer. The timing of this delay has been somewhat arbitrary. We evaluated the timing from T2 bladder cancer diagnosis to cystectomy, its impact on survival and potential causes of delay. A contemporary cohort of 214 consecutive patients presented with clinical T2 bladder cancer and underwent radical cystectomy as primary therapy. Clinicopathological parameters were maintained in an institutional database. A review of time to cystectomy, pathological stage, disease specific survival and OS was performed. Variables were tested in univariate and multivariate analyses. The log rank test was used for exploratory analyses to determine meaningful delay cutoff points. Mean followup and time to cystectomy in the entire cohort was 40 months and 60 days, respectively. A significant disease specific survival and OS advantage was observed in patients undergoing cystectomy by 93 days or less (3.1 months) compared to greater than 93 days (p = 0.05 and 0.02, respectively). Pathological staging was similar between the groups (p = 0.15). A multivariate benefit in OS was observed in patients treated with...Continue Reading

References

Jul 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J LoehrerB A Lowe
Jun 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C J LogothetisR G Kilbourn
Jul 16, 1997·Journal of the National Cancer Institute·S B FoxA L Harris
Mar 7, 1998·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·E D ChristensenG Petterson
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P SteinD G Skinner
Apr 5, 2002·Japanese Journal of Clinical Oncology·Isao HaraSadao Kamidono
Apr 27, 2002·Cancer Chemotherapy and Pharmacology·Jing LiuKenneth K Chan
Feb 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jenny HuangWilliam J Mackillop
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephan MadersbacherUrs E Studer
Dec 19, 2003·The Urologic Clinics of North America·Bernard H BochnerCheryl T Lee

❮ Previous
Next ❯

Citations

Jun 20, 2007·Der Urologe. Ausg. A·M RetzJ E Gschwend
Nov 23, 2006·World Journal of Urology·Peter C BlackColin P Dinney
Nov 2, 2006·World Journal of Urology·Ahmad Shabsigh, Bernard H Bochner
Dec 20, 2007·World Journal of Urology·Piyush K AgarwalAshish M Kamat
Oct 11, 2011·World Journal of Urology·Matthias MayMaximilian Burger
Nov 29, 2007·Current Urology Reports·Richard E Hautmann
Jul 7, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A FontR Rosell
Apr 18, 2009·Current Opinion in Oncology·Carl J Bischoff, Peter E Clark
Aug 21, 2012·Cancer Management and Research·Hans Goethuys, Hein Van Poppel
Jun 23, 2009·Drugs·Neeraj Agarwal, Maha Hussain
Aug 5, 2011·Indian Journal of Urology : IJU : Journal of the Urological Society of India·Rishi Nayyar, Narmada P Gupta
Mar 5, 2013·World Journal of Urology·Vincent BourgadeMorgan Rouprêt
May 19, 2009·The Journal of Urology·Alon Z WeizerRajal B Shah
May 20, 2015·International Journal of Urology : Official Journal of the Japanese Urological Association·Nobuyuki HinataMasato Fujisawa
Jul 29, 2010·Cancer·Brent K HollenbeckDavid C Miller
Apr 6, 2016·Scandinavian Journal of Urology·Derek BosBobby Shayegan
Mar 8, 2008·BJU International·Vitaly MargulisShahrokh F Shariat
Nov 28, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lorraine M ElitHsien-Yeang Seow
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Omer Dizdar, Umut Demirci
Jul 14, 2007·Expert Review of Anticancer Therapy·John C KeferSteven C Campbell
Sep 9, 2008·Urologic Oncology·John C Kefer, Steven C Campbell
Dec 2, 2015·Therapeutic Advances in Urology·Dominic H Tang, Sam S Chang
Aug 31, 2018·International Journal of Molecular Sciences·Melissa P TanRobert A Huddart
Mar 30, 2018·Minerva urologica e nefrologica = The Italian journal of urology and nephrology·Alessandro AntonelliClaudio Simeone
Apr 25, 2008·The Journal of Urology·Alan M Nieder
Apr 19, 2011·The Journal of Urology·Daniel O'BrienWilliam J Catalona

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.